ABP-745 for Gout
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called ABP-745, a potential drug for acute gout, a type of arthritis that causes sudden and severe joint pain and swelling. The goal is to determine if ABP-745 can reduce pain and swelling more effectively than the usual treatment, colchicine, or a placebo (a look-alike pill with no active drug). Participants will be divided into groups to receive different doses of ABP-745, colchicine, or a placebo. Candidates may qualify if they have experienced at least two gout flare-ups in the past year and are currently undergoing an acute gout attack. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of people.
Will I have to stop taking my current medications?
If you are taking medications for gout like allopurinol, febuxostat, or probenecid, you must stay on a stable dose throughout the study. However, you cannot take certain other medications like prednisone, NSAIDs, or colchicine shortly before starting the trial.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Earlier studies have shown that ABP-745 is safer and easier to tolerate than current gout medications. Research on animals and early human tests suggest that this treatment is generally well-received. Reports indicate that ABP-745 effectively reduces symptoms of acute gout, such as pain and swelling, with fewer safety issues. Animal studies also support its good safety profile. This suggests that ABP-745 might be a safer choice for managing gout flare-ups compared to some existing treatments.12345
Why do researchers think this study treatment might be promising for gout?
Researchers are excited about ABP-745 for gout because it targets inflammation in a potentially more effective way than current treatments. Unlike standard options like allopurinol and colchicine, which primarily aim to lower uric acid levels or reduce inflammation, ABP-745 may work through a novel mechanism that directly tackles the inflammatory pathways involved in gout attacks. This new approach could lead to faster relief of symptoms and improved long-term outcomes for patients dealing with this painful condition. With two different doses being explored, ABP-745 offers hope for a more tailored and efficient treatment option.
What evidence suggests that this trial's treatments could be effective for acute gout?
Research shows that ABP-745 is designed to alleviate pain and swelling from sudden gout attacks. Early studies with healthy participants suggest that the drug is generally safe and does not cause major side effects. While specific results on its effectiveness for gout are not yet available, the treatment aims to avoid the safety issues often associated with current gout medications. ABP-745 reduces inflammation, which is crucial for managing gout symptoms. Participants in this trial may receive varying doses of ABP-745, Colchicine, or a placebo for comparison.13678
Are You a Good Fit for This Trial?
This trial is for individuals experiencing an acute gout flare-up. Participants should have a history of gout and be currently suffering from pain and swelling due to the condition. Specific inclusion or exclusion criteria are not provided, but typically these would relate to overall health status, age range, and possibly previous treatments.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ABP-745 or colchicine or placebo to evaluate efficacy in reducing pain and swelling
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ABP-745
Find a Clinic Near You
Who Is Running the Clinical Trial?
Atom Therapeutics Co., Ltd
Lead Sponsor